Author

Elena Korneva

Observed names: E Korneva, E. Korneva, E. V. Korneva, Elena V. Korneva

Institution: R-Pharm (Russia)

Observed institutions: Keio University, Metroplex Clinical Research Center, R-Pharm (Russia), Medical University of Vienna, The University of Texas Southwestern Medical Center

ORCID: 0000-0002-4085-5869

Observed ORCID: 0000-0002-4085-5869

OpenAlex ID: A5038419678

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

2022 · Josef S. Smolen, Eugen Feist, et al. · New England Journal of Medicine · 88

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

2021 · Evgeniy Nasonov, Saeed Fatenejad, et al. · Annals of the Rheumatic Diseases · 79

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

2022 · Eugen Feist, Saeed Fatenejad, et al. · Annals of the Rheumatic Diseases · 49

Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies

2021 · Mark C. Genovese, Patrick Durez, et al. · European Journal of Rheumatology · 10

P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study

2021 · Eugen Feist, Saima Chohan, et al. · Rheumatology · 6

Olokizumab Treatment of both Western and Asian Patients with Rheumatoid Arthritis who have Failed Anti-Tnf Treatment Results in Sustained Improvements in Patient-Reported Outcomes

2016 · MC Genovese, P Durez, et al. · Value in Health · 4

P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy

2021 · Eugen Feist, Saeed Fatenejad, et al. · Rheumatology · 2

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

2023 · E. Feist, S. Fatenejad, et al. · Modern Rheumatology Journal · 1

Pharmacokinetics of Fimasartan, a novel angiotensin II receptor type 1 antagonist in Russian population

2016 · Zh. D. Kobalava, Yu. V. Kotovskaya, et al. · Arterial’naya Gipertenziya (Arterial Hypertension) · 1

Efficacy and safety of fimasartan, a new angiotensin-receptor blocker, compared to losartan in mild-to-moderate hypertension

2016 · N. E. Zvartau, A. O. Konradi, et al. · Arterial’naya Gipertenziya (Arterial Hypertension)

Pp.lb01.25: Pharmacokinetic Parameters of Fimasartan in Russian Patients With Arterial Hypertension

2015 · Z. Kobalava, E. Korneva, et al. · Journal of Hypertension

Распространенность генов CYP2C9 и VKORC1 у пациентов с фибрилляцией предсердий в Смоленской области

2011 · Elena Korneva, Svetlana Rachina, et al. · Вестник Смоленской государственной медицинской академии

Works count: 12

Citation count: 240

H-index: 5

I10-index: 4